Pfizer (NYSE:PFE) said yesterday that it inked a multi-year extension of its collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation to improve access to the company’s injectable contraceptive, Sayana Press, for women in developing countries.
The pharma giant’s product uses Becton Dickinson‘s (NYSE:BDX) Uniject delivery system to administer a long-acting, reversible contraceptive. The prefilled, single-use system does not require a patient to prepare a needle and syringe, and it can be administered by a health worker outside of a clinical setting. Previously, it was sold to purchasers at $1.00 per dose. According to the new agreement, Sayana Press will be available to qualified purchases at 85¢ per dose.